References
- Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022. doi:10.1038/s41591-022-01840-0.
- Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, Canas LS, Graham MS, Klaser K, Modat M, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):1–2. doi:10.1016/S1473-3099(21)00460-6.
- Florentino P, Alves F, Cerqueira-Silva T, de Araujo Oliveira V, Bertoldo Júnior J, Jantsch A, Penna G, Boaventura V, Werneck G, Pearce N, et al. Vaccine effectiveness of CoronaVac against symptomatic and severe COVID-19 among children in Brazil during the Omicron period. Res Sq [preprint]. 2022. doi:10.21203/rs.3.rs-1604882/v1.
- Araos R, Jara A, Undurraga E, Zubizarreta J, Gonzalez C, Acevedo J, Pizarro A, Vergara V, Marchant MS, Gilabert R, et al. Effectiveness of CoronaVac in children 3 to 5 years during the omicron SARS-CoV-2 outbreak. Res Sq [preprint]. 2022. doi:10.21203/rs.3.rs-1440357/v1.
- Tayar E, Abdeen S, Alah MA, Chemaitelly H, Bougmiza I, Ayoub HH, Kaleeckal AH, Latif AN, Shaik RM, Al-Romaihi HE, et al. Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. MedRxiv [preprint]. 2022. doi:10.1101/2022.05.09.22274802.